Aldeyra Therapeutics (ALDX) Other Non-Current Liabilities (2013 - 2014)
Aldeyra Therapeutics (ALDX) posted Other Non-Current Liabilities of $1.8 million for Q1 2014, down 50.01% on a QoQ basis from $3.5 million in Q4 2013.
Aldeyra Therapeutics (ALDX) Other Non-Current Liabilities (2013 - 2014) Analysis & Trends
Aldeyra Therapeutics' Other Non-Current Liabilities history runs 2 years deep, the most recent figure standing at $1.8 million for Q1 2014.
- Quarterly Other Non-Current Liabilities changed N/A year-over-year to $1.8 million in Q1 2014, while the trailing twelve-month figure through Mar 2014 was $1.8 million (changed N/A YoY) and the FY2013 annual result came in at $3.5 million, changed N/A from the prior year.
- Other Non-Current Liabilities was $1.8 million for Q1 2014 at Aldeyra Therapeutics, down from $3.5 million in the prior quarter.
- Across five years, Other Non-Current Liabilities topped out at $3.5 million in Q4 2013 and bottomed at $1.8 million in Q1 2014.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Oculis Holding AG | 65,899.61 Bn | 65,899.33 Bn | - |
| 2 | Nanobiotix | 1,933.82 Bn | 1,933.76 Bn | - |
| 3 | Akari Therapeutics | 1,022.34 Bn | 1,022.34 Bn | - |
| 4 | BeOne Medicines | 472.68 Bn | 467.89 Bn | 1.35 Bn |
| 5 | Vertex Pharmaceuticals | 122.24 Bn | 114.99 Bn | 2.59 Bn |
| 6 | Regeneron Pharmaceuticals | 70.08 Bn | 61.33 Bn | 3.31 Bn |
| 7 | Belite Bio | 62.46 Bn | 62.46 Bn | - |
| 8 | Argenx Se | 55.93 Bn | 50.75 Bn | 1.41 Bn |
| 9 | Alnylam Pharmaceuticals | 37.59 Bn | 34.58 Bn | 959.66 Mn |
| 10 | Aldeyra Therapeutics | 94.70 Mn | 94.70 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2014 | 1.76 Mn |
| Dec 31, 2013 | 3.52 Mn |